0 79

Cited 23 times in

Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection

 Mi In Roh  ;  Su Jin Lim  ;  Ji Min Ahn  ;  Jong Baek Lim  ;  Oh Woong Kwon 
 Graefes Archive for Clinical and Experimental Ophthalmology, Vol.248(5) : 635-640, 2010 
Journal Title
 Graefes Archive for Clinical and Experimental Ophthalmology 
Issue Date
Aged ; Angiogenesis Inhibitors/administration & dosage* ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal, Humanized ; Aqueous Humor/metabolism* ; Bevacizumab ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/metabolism ; Choroidal Neovascularization/physiopathology ; Cytokines/metabolism* ; Female ; Humans ; Immunoassay ; Injections ; Macular Degeneration/drug therapy* ; Macular Degeneration/metabolism* ; Macular Degeneration/physiopathology ; Male ; Middle Aged ; Retreatment ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/metabolism ; Visual Acuity/physiology ; Vitreous Body
Age-related macular degeneration ; Aqueous humor ; Bevacizumab ; Interleukin-1 ; Vascular endothelial growth factor
BACKGROUND : To evaluate the changes in aqueous humor cytokine levels following consecutive intravitreal bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) injections in eyes with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). METHOD : Aqueous humor samples were collected at the time of intravitreal injection of 1.25 mg of bevacizumab every 7.0 (+/-2.0) weeks from ten eyes with AMD for the AMD group and during cataract surgery in nine eyes for the control group. Visual acuity with Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and central macular thickness (CMT) using optical coherence tomography were measured before each injection in the AMD group. Aqueous cytokine levels were determined by immunoassay using multi-analyte biochip array technology (Evidence investigator cytokine and growth factor biochip array, RANDOX laboratories Ltd., Crumlin, UK). RESULT : In the AMD group, mean +/- standard deviation(SD) aqueous VEGF levels decreased from 68.0 +/- 32.1 pg/ml at baseline to 26.3 +/- 19.0 pg/ml after the first injection (p = 0.028) and to 25.2 +/- 12.8 pg/ml after the second injection (p = 0.005). While CMT decreased from 307.7 +/- 102.0 mum to 206.8 +/- 141.5 microm (p = 0.037), ETDRS visual acuity increased from 17.6 +/- 11.7 letters to 22.0 +/- 15.6 letters after three consecutive injections (p = 0.017). CONCLUSION : Significantly decreased VEGF levels were noted after the first injection of bevacizumab. These levels were maintained after the second injection, which paralleled the change in visual acuity and CMT.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Oh Woong(권오웅)
Lim, Jong Baeck(임종백) ORCID logo https://orcid.org/0000-0003-0419-0422
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.